Gihan Ratnayake

The Royal Marsden NHS Foundation Trust, Londinium, England, United Kingdom

Are you Gihan Ratnayake?

Claim your profile

Publications (2)11.36 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Surgery is often advocated in patients with resectable pulmonary metastases from colorectal cancer (CRC). Our study aims to evaluate peri-operative chemotherapy in patients with metastastic CRC undergoing pulmonary metastasectomy. Methods Patients treated for CRC who underwent pulmonary metastasectomy by a single surgeon were identified. Outcome measures included survival, peri-operative complications, radiological and histological evidence of chemotherapy-induced lung toxicities. Results Between 1997 and 2009, 51 eligible patients were identified undergoing a total of 72 pulmonary resections. Thirty-eight patients received peri-operative chemotherapy, of whom 9 received an additional biological agent. Five-year overall survival rate was 72% in the whole cohort - 74% and 68% in those who received peri-operative chemotherapy (CS) and those who underwent surgery alone (S) respectively. Five-year relapse free survival rate was 31% in the whole cohort - 38% and ≤18% in CS and S groups respectively. Only 8% had disease progression during neoadjuvant chemotherapy. There were no post-operative deaths. Surgical complications occurred in only 4% of patients who received pre-operative chemotherapy. There was neither radiological nor histological evidence of lung toxicity in resected surgical specimens. Conclusions Peri-operative chemotherapy can be safely delivered to CRC patients undergoing pulmonary metastasectomy. Survival in this selected group of patients was favourable.
    BMC Cancer 08/2012; 12(1):326. DOI:10.1186/1471-2407-12-326 · 3.36 Impact Factor
  • Gihan Ratnayake · David Cunningham ·

    Nature Clinical Practice Oncology 04/2008; 5(3):132-3. DOI:10.1038/ncponc1044 · 8.00 Impact Factor